Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Robert Knight et al.|Blood|2017Cited by 1.5k
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Nirav N. Shah et al.|The Lancet|2021Cited by 456
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, Jeffrey R. Infante et al.|Cancer Discovery|2017Cited by 418
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Jennifer A. Woyach et al.|New England Journal of Medicine|2023Cited by 213
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancerDana E. Rathkopf, Andrew J. Armstrong, Manish R. Patel et al.|Annals of Oncology|2024Cited by 66